EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment

Manabu Seino iD, Satoru Nagase iD, Hideki Tokunaga iD, Wataru Yamagami iD, Yoichi Kobayashi iD, Tsutomu Tabata iD, Masanori Kaneuchi iD, Yasuyuki Hirashima iD, Hitoshi Niikura iD, Kiyoshi Yoshino iD, Kazuhiro Takehara iD, Tsukasa Baba iD und 2 weitere

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e15 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Manabu Seino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan. m-seino@med.id.yamagata-u.ac.jp. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cervical cancer, indicate appropriate current treatment methods for cervical cancer, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden of patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO Guideline Committee, based on a careful review of evidence gathered through the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise seven chapters and 5 algorithms. The main features of the 2022 revision are as follows: 1) added discussed points at the final consensus meeting; 2) revised the treatment methods based on the International Federation of Gynecology and Obstetrics 2018 staging system; 3) examined minimally invasive surgery based on Laparoscopic Approach to Cervical Cancer trial; 4) added clinical question (CQ) for treatments of rare histological types, gastric type, and small-cell neuroendocrine carcinoma; 5) added CQ for intensity-modulated radiation therapy; 6) added CQ for cancer genomic profiling test; and 7) added CQ for cancer survivorship. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2022 for the Treatment of Uterine Cervical Cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsFemaleHumansPregnancyJapanNeoplasm StagingPrognosisSocieties, Medical

Stichwörter der Autor:innen

Clinical Practice GuidelineGuideline, JapanUterine Cervical CancerUterine Cervical Neoplasms

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan. m-seino@med.id.yamagata-u.ac.jp.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
  • Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kyorin University, Faculty of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan.

ORCID-Profile: Manabu Seino, Satoru Nagase, Hideki Tokunaga, Wataru Yamagami, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kaneuchi, Yasuyuki Hirashima, Hitoshi Niikura, Kiyoshi Yoshino, Kazuhiro Takehara, Tsukasa Baba, Hidetaka Katabuchi, Mikio Mikami

Zitieren

APA

Seino, M., Nagase, S., Tokunaga, H., Yamagami, W., Kobayashi, Y., Tabata, T., Kaneuchi, M., Hirashima, Y., Niikura, H., Yoshino, K., Takehara, K., Baba, T., Katabuchi, H., & Mikami, M. (2024). Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e15

Vancouver

Seino M, Nagase S, Tokunaga H, Yamagami W, Kobayashi Y, Tabata T, et al. Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e15

BibTeX
@article{Seino2024,
  author = {Seino, Manabu and Nagase, Satoru and Tokunaga, Hideki and Yamagami, Wataru and Kobayashi, Yoichi and Tabata, Tsutomu and Kaneuchi, Masanori and Hirashima, Yasuyuki and Niikura, Hitoshi and Yoshino, Kiyoshi and Takehara, Kazuhiro and Baba, Tsukasa and Katabuchi, Hidetaka and Mikami, Mikio},
  title = {Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e15}
}
Kostenlos starten →